Clinically translated ischemic stroke genomics

Stroke

Volumn 35, Issue 11 SUPPL. 1, 2004, Pages 2735-2739

  Meschia, James F ^a  

^a MAYO CLINIC   (United States)

Author keywords

Genetics; Outcome; Stroke, ischemic

Indexed keywords

ACETYLSALICYLIC ACID; ADDUCIN; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; PHOSPHOLIPID ANTIBODY; PLACEBO; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ANTIHYPERTENSIVE THERAPY; CADASIL; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONFERENCE PAPER; DIURETIC THERAPY; FAMILY HISTORY; GENETIC RISK; GENOMICS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HERITABILITY; HUMAN; LEUKOARAIOSIS; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME; TWINS;

CEREBROVASCULAR ACCIDENT; HUMANS; PHARMACOGENETICS; PHENOTYPE;

EID: 7644230130     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000143156.32467.fd     Document Type: Conference Paper

References (40)

1. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir SM, Einarsson OB, Gudjonsdottir HM, Hawkins M, Gudmundsson G, Gudmundsdottir H, Andrason H, Gudmundsdottir AS, Sigurdardottir M, Chou TT, Nahmias J, Goss S, Sveinbjornsdottir S, Valdimarsson EM, Jakobsson F, Agnarsson U, Gudnason V, Thorgeirsson G, Fingerle J, Gurney M, Gudbjartsson D, Frigge ML, Kong A, Stefansson K, Gulcher JR. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet. 2003;35:131-138.
2. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, Samani NJ, Gudmundsson G, Grant SF, Thorgeirsson G, Sveinbjornsdottir S, Valdimarsson EM, Matthiasson SE, Johannsson H, Gudmundsdottir O, Gurney ME, Sainz J, Thorhallsdottir M, Andresdottir M, Frigge ML, Topol EJ, Kong A, Gudnason V, Hakonarson H, Gulcher JR, Stefansson K. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233-239.
3. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke. 2004;35:212-227.
4. Marenberg ME, Zdravkovic S, Pedersen NL, deFair U. The effect of age on the genetic susceptibility to mortality from stroke in men and women: 35 years of follow-up in the Swedish Twin Registry. 29th International Stroke Conference, San Diego, Calif; 2004.
5. Adams HP, Jr, Bendixen BH, Rappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, III. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
6. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes: a family history study. Stroke. 2003;34:1364-1369.
7. Polychronopoulos P, Gioldasis G, Ellul J, Metallinos IC, Lekka NP, Paschalis C, Papapetropoulos T. Family history of stroke in stroke types and subtypes. J Neurol Sci. 2002;195:117-122.
8. Meschia JF, Atkinson EJ, O'Brien PC, Brott TG, Brown RD, Jr., Hardy J. Familial clustering of stroke according to proband age at onset of presenting ischemic stroke. Stroke. 2003;34:e89-e91.
9. Peto R, Doll R. There is no such thing as aging. BMJ. 1997;315:1030-1032.
10. Sayed-Tabatabaei FA, Houwing-Duistermaat JJ, van Duijn CM, Witteman JC. Angiotensin-converting enzyme gene polymorphism and carotid artery wall thickness: a meta-analysis. Stroke. 2003;34:1634-1639.
11. Netea MG, Hijmans A, van Wissen S, Smilde TJ, Trip MD, Kullberg BJ, de Boo T, Van der Meer JW, Kastelein JJ, Stalenhorf AF. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. Eur J Clin Invest. 2004;34:94-99.
12. Fox CS, Larson MG, Corey D, Feng D, Lindpaintner K, Polak JF, Wolf PA, D'Agostino RB, Tofler GH, O'Donnell CJ. Absence of association between polymorphisms in the hemostatic factor pathway genes and carotid intimai medial thickness: the Framingham Heart Study. Stroke. 2004;35:e65-67.
13. Hassan A, Lansbury A, Catto AJ, Guthrie A, Spencer J, Craven C, Grant PJ, Bamford JM. Angiotensin converting enzyme insertion/deletion genotype is associated with leukoaraiosis in lacunar syndromes. J Neurol Neurosurg Psychiatry. 2002;72:343-346.
14. Kohara K, Fujisawa M, Ando F, Tabara Y, Niino N, Miki T, Shimokata H. MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the Japanese general population: The NILS-LSA Study. Stroke. 2003;34:1130-1135.
15. Carmelli D, DeCarli C, Swan GE, Jack LM, Reed T, Wolf PA, Miller BL. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998;29:1177-1181.
16. Turner ST, Jack CR, Fornage M, Mosley TH, Boerwinkle E, de Andrade M. Heritability of leukoaraiosis in hypertensive sibships. Hypertension. 2004;43:483-487.
17. Donahue CP, Kosik KS. Distribution pattern of Notch3 mutations suggests a gain-of-function mechanism for CADASIL. Genomics. 2004;83:59-65.
18. rd-6A decades. Radiology. 2003;229:683-690.
19. Martiskainen M, Pohjasvaara T, Mikkelsson J, Mantyla R, Kunnas T, Laippala P, Ilveskoski E, Kaste M, Karhunen PJ, Erkinjuntti T. Fibrinogen gene promoter -455 A allele as a risk factor for lacunar stroke. Stroke. 2003;34:886-891.
20. Myllykangas L, Polvikoski T, Sulkava R, Notkola IL, Rastas S, Verkkoniemi A, Tienari PJ, Niinisto L, Hardy J, Perez-Tur J, Kontula K, Haltia M. Association of lipoprotein lipase Ser447Ter polymorphism with brain infarction: a population-based neuropathological study. Ann Med. 2001;33:486-492.
21. Meschia JF. Addressing the heterogeneity of the ischemic stroke phenotype in human genetics research. Stroke. 2002;33:2770-2774.
22. Jeffs B, Clark JS, Anderson NH, Gratton J, Brosnan MJ, Gauguier D, Reid JL, Macrae IM, Dominiczak AF. Sensitivity to cerebral ischaemic insult in a rat model of stroke is determined by a single genetic locus. Nat Genet. 1997;16:364-367.
23. Gratton JA, Sauter A, Rudin M, Lees KR, McColl J, Reid JL, Dominiczak AF, Macrae IM. Susceptibility to cerebral infarction in the stroke-prone spontaneously hypertensive rat is inherited as a dominant trait. Stroke. 1998;29:690-694.
24. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci. 2003;4:399-415.
25. Broderick J, Lu M, Jackson C, Pancioli A, Tilley BC, Pagan SC, Kothari R, Levine SR, Marier JR, Lyden PD, Haley EC, Jr., Brott T, Grotta JC. Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann Neurol. 2001;49:736-744.
26. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, Siscovick DS, Bis J, Lumley T, Longstreth WT, Jr., Rosendaal FR. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA. 2002;287:1680-1689.
27. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
28. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP, Jackson CM, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-1451.
29. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, Murphy A, Lu Y, Costigan TM, Rhine C, Levin B, Triplett DA, Mohr JP. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576-584.
30. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002;105:2625-2631.
31. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, Kittner S, Leurgans S. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA. 2003;289:2947-2957.
32. Weisberg LA. The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. Neurology. 1993;43:27-31.
33. Moore JH, Ritchie MD. The challenges of whole-genome approaches to common diseases. JAMA. 2004;291:1642-1643.
34. Treger I, Froom P, Ring H, Friedman G. Association between apolipoprotein E4 and rehabilitation outcome in hospitalized ischemic stroke patients. Arch Phys Med Rehabil. 2003;84:973-976.
35. McCarron MO, Muir KW, Nicoll JA, Stewart J, Currie Y, Brown K, Bone I. Prospective study of apolipoprotein E genotype and functional outcome following ischemic stroke. Arch Neurol. 2000;57:1480-1484.
36. Dunn LT, Stewart E, Murray GD, Nicoll JA, Teasdale GM. The influence of apolipoprotein E genotype on outcome after spontaneous subarachnoid hemorrhage: a preliminary study. Neurosurgery. 2001;48:1006-1011.
37. McCarron MO, Muir KW, Weir CJ, Dyker AG, Bone I, Nicoll JA, Lees KR. The apolipoprotein E epsilon 4 allele and outcome in cerebrovascular disease. Stroke. 1998;29:1882-1887.
38. Liu Y, Laakso MP, Karonen JO, Vanninen RL, Nuutinen J, Soimakallio S, Aronen HJ. Apolipoprotein E polymorphism and acute ischemic stroke: a diffusion- and perfusion-weighted magnetic resonance imaging study. J Cereb Blood Flow Metab. 2002;22:1336-1342.
39. Carter AM, Catto AJ, Bamford JM, Grant PJ. Association of the platelet glycoprotein IIb HPA-3 polymorphism with survival after acute ischemic stroke. Stroke. 1999;30:2606-2611.
40. Carter AM, Catto AJ, Grant PJ. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation. 1999;99:2423-2426.